Serious dermatologic reactions in children

Current Opinion in Pediatrics

Volumn 9, Issue 4, 1997, Pages 388-395

  Knowles, Sandra ^a   Shapiro, Lori ^a   Shear, Neil H ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ALLOPURINOL; AMOXICILLIN; ANTIHISTAMINIC AGENT; AZATHIOPRINE; BETA LACTAM ANTIBIOTIC; CARBAMAZEPINE; CEFACLOR; CEFPROZIL; CEPHALOSPORIN; CORTICOSTEROID; DAPSONE; FUROSEMIDE; HYDRALAZINE; LAMOTRIGINE; LATEX; LORACARBEF; MINOCYCLINE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENOBARBITAL; PHENYTOIN; PIROXICAM; PREDNISONE; PROCAINAMIDE; SULFAMETHOXAZOLE; SULFONAMIDE; TETRACYCLINE; TETRACYCLINE DERIVATIVE; TRIMETHOPRIM;

ADOLESCENT; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTHRALGIA; CHILD; CHILDHOOD MORTALITY; CLINICAL SKIN REACTION; DERMATOLOGY; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG TOXICITY; DYSPNEA; EOSINOPHILIA; ERYTHROPOIETIC PROTOPORPHYRIA; FEMALE; FEVER; HUMAN; HYPERSENSITIVITY REACTION; HYPOTENSION; LUPUS ERYTHEMATOSUS; LYMPHADENOPATHY; MALE; MORBIDITY; ORAL DRUG ADMINISTRATION; PORPHYRIA; PORPHYRIA CUTANEA TARDA; PRIORITY JOURNAL; RASH; REVIEW; RISK FACTOR; SERUM SICKNESS; STEVENS JOHNSON SYNDROME; TOPICAL DRUG ADMINISTRATION; TOXIC EPIDERMAL NECROLYSIS; URTICARIA;

EID: 0030832143     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-199708000-00014     Document Type: Review

References (60)

1. McKenzie M, Marchall G, Netzloff M, Cluff L: Adverse drug reactions leading to hospitalization in children. J Pediatr 1976, 89:487-490.
2. Choonara I, Harris F: Adverse drug reactions in medical inpatients. Arch Dis Child 1984, 59:578-580.
3. Prussick R, Knowles S, Shear N: Cutaneous drug reactions. Curr Probl Dermatol 1994, 6:81-124.
4. Kramer M, Hutchinson T, Flegel K, Naimark L, Contardi R, et al.: Adverse drug reactions in general pediatric outpatients. J Pediatr 1985, 106:305-310.
5. Meyboom R: Adverse drug reaction to drugs in children, experiences with "spontaneous monitoring" in Netherlands. Bratislarske Lekarske Listy 1991, 92:554-559.
6. Heckbert S, Stryker W, Coltin K, Manson J, Platt R: Serum sickness in children after antibiotic exposure: estimates of occurence and morbidity in a health maintenance organization population. Am J Epidemiol 1990, 132:336-342.
7. Stricker B, Vandenbroek J, Keuning J, Eberhardt W, Heuben HGJ, Johnson M, Blok ADR: Cholestatic hepatitis due to antibacterial combination of amoxicillin and clavulanic acid (Augmentin). Dig Dis Sci 1989, 34:1576-1580.
8. Martin J, Abbott G: Serum sickness like illness and antimicrobials in children. N Z Med J 1995, 108:123-124.
9. Vial T, Pont J, Pham E, Rabilloud M, Descotes J: Cefaclor-associated serum sickness-like disease: eight cases and review of the literature. Ann Pharmacother 1992, 26:910-914.
10. Kearns G, Wheeler J, Childress S, Letzig L: Serum sickness-like reactions to cefaclor: role of hepatic metabolism and individual susceptibility. J Pediatr 1994, 125:805-811.
11. Lowery N, Kearns G, Young R, Wheeler J: Serum sickness-like reactions associated with cefprozil therapy. J Pediatr 1994, 125:325-328.
12. Harel L, Amir J, Livni E, Strassberg R, Varsano I: Serum sickness-like reaction associated with minocycline therapy in adolescents. Ann Pharmacother 1996, 30:481-483. Five adolescents developed a fever, rash, and arthralgias/arthritis after taking minocycline for 10 to 30 days; this reaction was typical of symptoms associated with serum sickness-like reaction. Four patients were receiving minocycline for the treatment of acne and one patient received the drug for pneumonia.
13. Knowles S, Shapiro L, Shear N: Serious adverse reactions induced by minocycline: a report of 13 patients and review of the literature. Arch Dermatol 1996, 132:934-937. The authors of this study identified 17 cases of hypersensitivity syndrome reaction, 7 cases of serum sickness-like reaction, and 25 cases of drug-induced lupus in their review of two databases and the literature. Serum sickness-like reactions and hypersensitivity syndrome reactions due to minocycline occurred within approximately 4 weeks of initiation of therapy, whereas drug-induced lupus occurred on average 2 years after the start of therapy.
14. Grammer L: Cefaclor serum sickness. JAMA 1996, 275:1152-1153.
15. Gough A, Chapman S, Wagstaff K, EMery P, Elias E: Minocycline-induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ 1996, 312:169-172. Eleven cases of minocycline-induced systemic lupus erythematosus, 16 cases of hepatitis, and seven additional cases are reviewed. Two patients died while taking the drug for acne and a third required a liver transplant. In five of the cases, rechallenge resulted in recurrence of the drug reaction.
16. Byrne PAC, Williams BO, Pritchard MH: Minocycline-related lupus. British J Rheumatol 1994, 33:674-676.
17. Matsuura T, Shimizu Y, Fujimoto H, Miyazaki T, Kano S: Minocycline-related lupus. Lancet 1992, 340:1553.
18. Roujeau JC, Stern R: Severe adverse cutaneous reactions to drugs. N Engl J Med 1994, 331:1272-1285.
19. Gupta A, Eggo M, Uetrecht J, et al.: Drug-induced hypothyroidism: the thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides. Clin Pharmacol Ther 1992, 51:56-67.
20. Vittorio C, Muglia J: Anticonvulsant hypersensitivity syndrome. Arch Intern Med 1995, 155:2285-2290. This is a good overview of the anticonvulsant hypersensitivity syndrome including clinical features, mechanisms, in vitro testing, and treatment and prognosis. Two cases of the anticonvulsant hypersensitivity syndrome are also presented.
21. Okuyama R, Ichinohasama R, Tagamai H: Carbamazepine induced erythroderma with systemic lymphadenopathy. J Dermatol 1996, 23:489-494.
22. Case records of the Massachusetts General Hospital: weekly clinicopathological exercises. Case 26-1996: a sever-year old boy with fever, lymphadenopathy, hepatosplenomegaly, and prominent eosinophilia. N Engl J Med 1996, 335:577-584.
23. Konishi G, Naganuma Y, Hongo K, Murakami M, Yamatani M, Okada T: Carbamazepine-induced skin rash in children with epilepsy. Eur J Pediatr 1993, 152:605-608.
24. Shear N, Spielberg S: Anticonvulsant hypersensitivity syndrome, in vitro assessment of risk. J Clin Invest 1988, 82:1826-1832.
25. Spielberg S, Gordon G, Blake D, Mellits D, Bross D: Anticonvulsant toxicity in vitro: possible role of arena oxides. J Pharmacol Exp Ther 1981, 217:386-389.
26. Alldredge B, Knutsen A, Ferriero D: Antiepileptic drug hypersensitivity syndrome: In vitro and clinical observations. Pediatr Neurol 1994, 10:169-171.
27. Besag F, Wallace S, Dlac O, Alving J, Spencer S, Hosking G: Lamotrigine for the treatment of epilepsy in childhood. J Pediatr 1995, 127:991-997.
28. Shear N, Spielberg S, Grant D, Tang B, Kalow W: Differences in metabolism of sulfonamides presdisposing to idiosyncratic toxicity. Ann Intern Med 1986, 105:179-187.
29. Knowles S, Gupta A, Shear N, Sauder D: Azathioprine hypersensitivity-like reactions: a case report and a review of the literature. Clin Exp Dermatol 1995, 20:353-356.
30. Parneix-Spake A, Bastuji-Garin S, Lobut J, Erner J, Guyet-Rousset P, Revuz J, Roujeau JC: Minocycline as possible cause of severe and protracted hypersensitivity drug reaction. Arch Dermatol 1995, 131:490-491.
31. Bastuji-Garin S, Rzany B, Stern R, Shear N, Naldi L, Roujeau J: Clinical classification of cases of toxic epidermal necrolysis, Stevens-Jonnson syndrome, and erythema multiforme. Arch Dermatol 1993, 129:92-96.
32. Rasmussen J: Erythema multiforme in children. Br J Dermatol 1976, 95:181-186.
33. Bianchine J, Macareg P, Lasagna L, Azarnoff DL, Brunk SF, Huidberg EF, Owen TA: Drugs as etiologic factors in the Stevens-Johnson syndrome. Am J Med 1968, 44:390-405.
34. Roujeau J, Kelly J, Naldi L, Rzany B, Stern RS, Anderson T, Auquier A, Bastuji-Garin S, Correia O, Locati F, et al.: Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995, 333:1600-1607.
35. Dooley J, Carnfield P, Gordon K, Carnfield CE, Smith E: Lamotrigine-induced rash in children. Neurology 1996, 46:240-242.
36. Mitchell P: Paediatric lamotrigine use hit by rash reports. Lancet 1997, 349:1080. Lamotrigine has been associated with severe skin rashes in children. The risk in children may be as high as 1 in 50, and the risk in adults is probably closer to 1 in 1000. Additional risk factors include simultaneous use of valproic acid, exceeding the recommended initial lamotrigine dose, or a too-rapid increase in dose.
37. Wadelius M, Karlsson T, Wadelius C, Rane A: Lamotrigine and toxic epidermal necrolysis. Lancet 1996, 348:1041.
38. Wolkenstein P, Charue D, Laurent P, Revuz J, Roujeau JC, Bagot M: Metabolic predisposition to cutaneous adverse drug reactions. Arch Dermatol 1995, 131:544-551.
39. Barone C, Bianchi M, Lee B, Mitra A: Treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome in children. J Oral Maxillofac Surg 1993, 51:264-268.
40. Patterson R, Miller M, Kaplan M, Doan J, Brown J, Detjen P, Grammer LC, Greenberger PA, Hogan MB, Latall J, et al.: Effectiveness of early therapy with corticosteroids in Stevens-Johnson syndrome: experience with 41 cases and a hypothesis regarding pathogenesis. Ann Allergy 1994, 73:27-34.
41. Prendville J, Hebert A, Greenwald M, Esterly N: Management of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Pediatr 1989, 115:881-887.
42. Anderson J: Allergic reactions to drugs and biologic agents. JAMA 1992, 268:2845-2857.
43. Taylor J, Praditsuwan P: Latex allergy: review of 44 cases including outcome and frequent association with allergic hand eczema. Arch Dermatol 1996, 132:265-271.
44. Sullivan T, Magera B: Recurrent allergic reactions to latex in a hospitalized pediatric patient. J Allergy Clin Immunol 1995, 96:423-425. A 10-month-old girl with biliary atresia was diagnosed with latex allergy. While in the hospital, the patient received a latex-containing pacifier. Within 1 hour, wheezing and upper airway obstruction led to respiratory failure. The patient fully recovered. Although latex allergy is not a new phenomenon in children, this case emphasizes that many sources of latex antigens are present in the hospital.
45. Lu L, Kurup V, Hoffman D, Kelly K, Murali P, Fink J: Characterization of a major latex allergen associated with hypersensitivity in spina bifida patients. J Immunol 1995, 155:2721-2728.
46. Knowles S, Shear N: Hypersensitivity to trimethoprim-sulfamethoxazole in HIV-infected patients. Opportunistic Complications of HIV 1995, 4:40-52.
47. McSherry G, Wright M, Oleske J: Frequency of serious adverse reactions to trimethoprim-sulfamethoxazole and pentamidine among children with human immunodeficiency virus 1 infection. Program and abstracts of the 28th International Conference on Antimicrobial AGents and Chemotherapy. Los Angeles, California; 1988.
48. Chanock S, Luginbuhl L, McIntosh K, Lipshultz S: Life-threatening reaction to trimethoprim/sulfamethoxazote in pediatric human immunodeficinecy virus infection. Pediatrics 1994, 93:519-521.
49. Lantner R: Ciprofloxacin desensitization in a patient with cystic fibrosis. J Allergy Clin Immunol 1995, 96:1001-1002.
50. Palusci V, Kaul A, Lawrence R, Haines K, Kwittken P: Rapid oral desensitization to trimethoprim-sulfamethoxazole in infants and children. Pediatr Infect Dis J 1996, 15:456-460. In a recent report, five children infected with HIV were desensitized to TMP-SMX using a rapid, 4-hour, oral protocol. Three children successully completed desensitization and started maintenance therapy; however, the other two children developed reactions during the desensitization. One patient developed localized pruritus that progressed despite treatment with diphenhydramine. In another patient, headache, shaking chills, and a fever developed 2 hours after completion of desensitization. TMP-SMX was discontinued. Two months later the patient was given dapsone and developed a similar reaction.
51. Kletzel M, Beck S, Elser J, Shock N, Burks W: Trimethoprim-sulfamethoxazole oral desensitization in hemophiliacs infected with human immunodeficiency virus with a history of hypersensitivity reactions. Am J Dis Child 1991, 145:1428-1429.
52. Kreuz W, Gungor T, Lotz C, Funk M, Komhube B: Treating through hypersensitivity to co-trimoxazole in children with HIV infection. Lancet 1990, 336:508-509.
53. Nagaraian R, Nelson R, Day N, RA: Trimethoprim-sulfamethoxazole sensitivity and desensitization in HIV-infected children. J Allergy Clin Immunol 1995, 95(1 part 2):287.
54. Yango M, Kim K, Evans R: Oral desensitization to trimethoprim-sulfamethoxazole in pediatric patients. Immun Allergy Pract 1992, 14:17-24.
55. Lang B, Finlayson L: Naproxen-induced pseudoporphyria in patients with juvenile rheumatoid arthritis. J Pediatr 1994, 124:639-642.
56. Kochevar I: Phototoxicity of nonsteroidal anti-inflammatory drugs. Arch Dermatol 1989, 125:824-826.
57. Roujeau J, Bioulac-Sage P, Bourseau C, Guillaume JC, Bernard P, Lok C, Plantin P, Claudy A, Delavierre C, Vaillant L, et al.: Acute generalized exanthematous pustulosis: analysis of 63 cases. Arch Dermatol 1991, 127:1333-1338.
58. Beylot C, Doutre M, Beylot-Bany M: Acute generalized exanthematous pustulosis. Semin Cutaneous Med Surg 1996, 15:244-249.
59. Palusci V, Kaul A, Lawrence R, Haines K, Kwittken P: Rapid oral desensitization to trimethoprim-sulfamethoxazole in infants and children. Pediatr Infect Dis J 1996, 15:456-460.
60. Recchia A, Shear N: Organization and functioning of an adverse drug reaction clinic. J Clin Pharmacol 1994, 34:68-79.